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Domiciliary use of transcutaneous electrical stimulation for patients with obstructive 
sleep apnoea: a conceptual framework for the TESLA home programme 
Running Head: Conceptual Framework TESLA home 
Key words: hypoglossal nerve stimulation, neural stimulation, CPAP, sleepiness, compliance 
 
Abstract 
Obstructive sleep apnoea (OSA) is a global health problem of increasing prevalence. 
Effective treatments are available with continuous positive airway pressure (CPAP) therapy 
and mandibular advancement devices (MAD). However, there is limited long-term adherence 
to therapy, as CPAP and MAD require permanent usage to avoid recurrence of the symptoms 
and adverse ill health. Alternative treatments would aid in the treatment cascade to manage 
OSA effectively whenever standard therapy has been trialled and failed. Hypoglossal nerve 
stimulation (HNS), an invasive approach to stimulate the pharyngeal dilator muscles of the 
upper airway during sleep, has been approved for the treatment of OSA by several healthcare 
systems in recent years. In parallel to the development of HNS, a non-invasive approach has 
been developed to deliver electrical stimulation. Transcutaneous Electrical Stimulation in 
Obstructive Sleep Apnoea (TESLA) uses non-invasive electrical stimulation to increase 
neuromuscular tone of the upper airway dilator muscles of patients with OSA during sleep. 
Data from previous feasibility studies and randomised controlled trials have helped to 
identify a subgroup of patients who are “responders” to this treatment. However, further 
investigations are required to assess usability, functionality and task accomplishment of this 
novel treatment. Consideration of these factors in the study design of future clinical trials will 
strengthen research methodology and protocols, improve patient related outcome measures 
and assessments, to optimise this emerging therapeutical option. In this review, we will 
introduce a conceptual framework for the TESLA home programme highlighting qualitative 
aspects and outcomes. 
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Introduction 
Obstructive sleep apnoea OSA is a global health problem associated with increased morbidity 
and mortality (1-4) . Patients with OSA experience repetitive upper airway closure during 
sleep which results in complete or partial cessation of airflow and causes oxygen 
desaturations; the airway closure leads to arousal from sleep, causing sleep fragmentation and 
daytime symptoms (5). OSA puts patients and others at risk of injury due to road traffic 
accidents (6, 7) caused by drowsiness and results in decreased neurocognitive function (8); 
OSA is associated with increased cardiovascular risk (3), hypertension (9, 10) and endothelial 
dysfunction (11), potentially contributing to myocardial infarction (12), stroke (13) and 
congestive heart failure (14). In addition to hypertension, risk factors associated with OSA 
include the male gender, age, obesity and smoking (15-18). 
 
Various factors contribute to upper airway obstruction during sleep (19, 20), including an 
abnormal anatomy (e.g. a narrow upper airway, enlarged tonsils, adenoids, retrognathia, 
obesity) and decreased neuromuscular tone (5, 21-24). Different anatomical levels of upper 
airway obstruction, the severity of OSA, posture and sleep state can all influence the efficacy 
of treatment (24-28). The best way to assess OSA severity is overnight polysomnography 
(“sleep study”), although symptom questionnaires and risk scores are used in the clinical 
setting and in population-based studies, and are essential to identify patients and define the 
syndrome (21, 29).  
 
Currently available treatments for OSA include continuous positive airway pressure (CPAP), 
mandibular advancement devices (MAD) and dental devices (30-33), lifestyle advice, weight 
loss and positional therapy (34), maxillo-mandibular surgery and ENT interventions (e.g. 
uvulopalatopharyngoplasty) (35) and, less frequently, non-invasive ventilation (5). CPAP 
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remains the Gold-standard treatment (36, 37), however, there is limited long-term adherence 
to CPAP and only about half of the patients will use it for the recommended four hours a 
night during at least five days a week after one year (5, 38, 39). The clear association between 
obesity and sleep apnoea (5, 23, 40-43) underlines the importance of developing effective 
treatments for weight loss to complement CPAP therapy.  
 
Hypoglossal nerve stimulation (HNS) has been recently developed as a novel treatment for 
OSA (44, 45). It requires the implantation of an stimulator cuff that is in contact with the 
hypoglossal nerve; it works by increasing the neuromuscular tone of the upper airway dilator 
muscles and thereby maintaining a patent upper airway during sleep (46-48). However, 
delivery of electrical stimulation is not exclusively an invasive option. A similar effect on the 
neuromuscular tone of the upper airway dilator muscles (49, 50) can be achieved non-
invasively by the use of transcutaneous electrical stimulation (46, 47). Patient-and-public-
involvement (PPI) surveys have shown that patients with OSA, even those who are adherent 
to CPAP therapy, are interested in the development and the testing of novel and particularly 
non-invasive treatments. Participation in and recruitment to future clinical trials will benefit 
from this involvement. 
 
In 2014, HNS was approved by the United States Food and Drug Administration (FDA) (51),  
and there are now post-market research registries and studies (e.g. Germany). In the UK, the 
National Institute for Health and Care Excellence (NICE) has published its interventional 
public guidance on HNS (IPG598) (52). The transcutaneous approach (TESLA) is currently 
undergoing a domiciliary feasibility study (TESLA home; NCT03160456, for the protocol 
see online supplement), involving three-months treatment and assessment. The TESLA home 
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methodology delivers electrical current via transcutaneous patches in the submental area, 
targeting the genioglossus muscle to maintain airway patency. This randomised controlled 
trial recruits patients with OSA (apnoea-hypopnoea index 5-35/hour) who have failed to use 
CPAP effectively (usage <4hours/night). Slim, overweight and mildly obese subjects (body-
mass index, BMI<32kg/m2) with an antero-posterior wall collapse and a slim neckline are 
known to represent the phenotype of the “responders” to this therapy. In particular women 
with OSA have been identified to benefit from this method (50). Similar to the selection 
criteria utilised for HNS, morbidly obese subjects with more severe OSA, multi-level or 
concentric upper airway collapse do not seem to sufficiently benefit and are in general 
excluded from upper airway stimulation trials. In addition to objectively measuring the 
effectiveness of electrical stimulation on preventing upper airway collapse, qualitative 
assessments are important to test the feasibility of such a novel treatment. Patients’ feedback 
will help to determine the feasibility of domiciliary transcutaneous electrical stimulation, 
design future clinical trials and inform further modification of the technology and the device 
(53). In this review, we will introduce a conceptual framework for the TESLA home 
programme to highlight qualitative aspects and outcomes. 
 
Conceptual Framework 
A framework was developed based on the conceptual idea to capture relevant aspects of the 
research undertaken in the TESLA programme, analyse and address health-regulatory body 
requirements (Medicines & Healthcare Products Regulatory Agency, MHRA) and produce 
qualitative data from clinical trials that are not directly linked to primary or secondary 
outcomes of the clinical trial (53). The published literature of electrical stimulation for sleep 
apnoea was screened and databases were searched (PubMed, Web of Science and Google 
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Scholar) using specific criteria (“electrical stimulation”, “transcutaneous electrical 
stimulation”, “hypoglossal nerve stimulation”, “Obstructive Sleep Apnoea”, “treatment”, 
“usability”, “medical devices”, “MHRA”); the found results were assessed by two 
independent reviewers (R.T., M.B.) and included for discussion with two other reviewers 
(M.N., J.S.) to generate and refine a model of a conceptual framework for the TESLA 
programme. The described conceptual framework was created with the intention to better 
assess the interaction between the three domains “medical device” (TESLA), “user” (patient) 
and “task” (OSA treatment) (53) which are defined as a) “usability”, b) “functionality” and c) 
“task accomplishment” (Figure 1): 
 
“Usability” 
The “usability” describes the degree to which the patient can make use of a medical 
device, to achieve quantifiable objectives efficiently, effectively and satisfactorily (54) 
(Figure 1). The user experience is complex and can, in part, be explained by a model that 
incorporates seven aspects of a treatment from the perspective of the user: whether it is 
usable, valuable, useful, desirable, accessible, credible and findable (55). “Usability” testing 
is considered a cornerstone in user-centred design, as it provides information about the 
machine–user interaction (56). 
The perceived “usability” of a treatment can affect adherence, which is the limiting factor for 
other sleep apnoea treatments like CPAP therapy and mandibular advancement devices. It is 
essential to understand this feature to better treat non-adherent patients. Long-term adherence 
depends on how individuals judge their personal need for a treatment relative to their 
concerns about its potential adverse effects. Adherence is a primary determinant of the 
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effectiveness of treatment, good long-term adherence improves the effectiveness of 
therapeutic interventions (57).  
To asses usability quantitative and qualitative approaches and methods can be used (58). 
Questionnaires (quantitative method) can rate the “ease of use”, “instructions for use”, and 
the “clarity of the design”, as well as ergonomics on given rating scales. With qualitative 
methods, such as (semi-)structured interviews, additional information can be gathered 
assessing patients’ “adherence to intended use”, or obvious design errors. The collected 
quantitative and qualitative data can then be used to address issues of “usability” and improve 
the machine-user interaction. Patients’ diaries to record practicability and potential adverse 
events can further measure “usability” of transcutaneous electrical stimulation for OSA (59). 
Psychological and personal aspects of a patient are essential characteristic when discussing 
“usability”, as they will affect any interaction with medical devices (60-62). Additionally, the 
attitude to treatment can be positive, negative or neutral based on previous experiences and 
expectations, as it is set out in motivational theories, such as the Valence-Instrumentality-
Expectancy (V-I-E) model (63). Motivation to use a device can therefore be explained as a 
multiplied connection of expectancy of a certain outcome (“the device will help to improve 
my health”) and the value of the result (“better health is of high relevance to the patient”). 
The following assessment can assist to address usability of the method: 
• Patient comfort and device acceptance 
Semiquantitative visual analogue scales can be used to assess the comfort of a new 
treatment (‘very much/very good’/”0” points, to ‘not at all/terrible’/”10”points) (53). 
In the context of TESLA, this can be used to identify adverse effects that can arise 
from the treatment, such as ‘skin discomfort’.     
• Qualitative and descriptive parameters and feedback  
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Patient feedback about usage, acceptance, problems and perceived benefits, may 
assess acceptability of a novel treatment.  Difficulties with the device, such as 
reliability, faults, ease of use, can be useful to modify the feasibility of the machine 
and, in the case of the TESLA programme, also the skin interface (hydrogel/patches). 
In the context of TESLA-home the described features play an important role (Figure 2; online 
supplement) and patient-and-public-involvement (PPI) (64) was undertaken at an early stage 
to understand the user, the task and physiological requirements, encourage early and active 
involvement, incorporate user-centred evaluations, address the entire user experience, 
encourage a multi-disciplinary design, and continuously engage with the users during the 
process (ISO 9241-210) (65). 
 
 “Functionality”  
The “functionality” tests the interaction between the ‘device’ and the ‘task’, it could also be 
described as efficacy in achieving a sufficient contraction of the dilator muscles of the upper 
airway to avoid upper airway obstruction (Figure 1). It assesses whether the muscles are 
sufficiently stimulated, and is further characterised by the suitability of the method, accuracy, 
interoperability, security, and functionality compliance; these features aim to satisfy the 
stated or implied needs (66). To maximise the effect and increase the neuromuscular tone of 
the genioglossus, improve upper airway patency and, thereby, treat OSA, some parameters 
including several basic properties of the medical device such as current, pulse width, 
stimulation frequency, wave form and pad shapes (size, location, uni- vs bilateral stimulation, 
material), and stimulation timing (triggered, intermittent, continuous) could be varied to 
further refine the treatment. These variables impact on the generated force, the fatiguability 
on the neuromuscular junction, the skin sensation and the tolerability of the method. 
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Relevant MHRA guidelines (67) 
The MHRA have issued relevant guidance on device resilience. To be resilient, the medical 
device’s functioning and performance should not be affected adversely through normal 
conditions of use over time. Furthermore, the device measurements and outputs must be 
accurate and remain so for the duration of the devices use with any accuracy limits clearly 
specified. Any measurements made should be expressed in the appropriate units as described 
in the Council Directive 80/181/EEC, and functions involving measuring and monitoring 
should be developed according to ergonomic principles. Devices involving electronic systems 
must be designed to function according to their intended use with ensured reliability and 
repeatability of performance.  
 
Specific to the TESLA methodology, it is important to measure a number of quantitative 
variables that help the understanding of the effect on the targeted muscles, describe 
physiological changes on the airway structure and the skin sensation of the electrical activity: 
• Imaging to observe muscle contraction and improvement in upper airway patency  
A) Upper airway magnetic resonance imaging (MRI) or computer tomography (CT) 
can be used to accurately visualize and calculate the diameter (mm2) of the upper 
airway awake and during sleep, as well as with the stimulation turned ‘on’ or ‘off’.  
B) Ultrasound is ubiquitous available in hospitals and can be used to identify and 
localise upper airway obstruction (68). The genioglossus can be visualized in 
different planes (49, 68) and the contraction of this muscle during stimulation can 
be tested at the bedside. Ultrasound measurements (frequency 5 to 13 MHz, 
Figure 3) can track significant contraction in the genioglossus during stimulation. 
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C) Endoscopy of the upper airway is an option to evaluate the severity of upper 
airway obstruction (69, 70) and offers the chance to assess upper airway patency 
during stimulation (Figure 4). 
• Electromyography of the submental muscles can record targeted muscle activity (49, 
71-73). 
For the TESLA home trial, physiological measurements focus on upper airway morphology 
and muscle contractions during electrical stimulation using ultrasound, upper airway 
endoscopy in the awake participants and functional assessments (see online supplement); 
these measurements are available at the bedside in most clinical settings. 
 
“Task accomplishment”  
The interaction between the user and the task/goal can be further described to determine “task 
accomplishment”, which can be assessed subjectively as well as objectively. Patients’ 
preconception of what they believe resembles a successful treatment compared with the 
treating teams’ point of view may not be entirely compatible, as they can prioritise different 
criteria (e.g. sleepiness vs apnoea-hypopnoea index (AHI)). 
Objectively, treatment data can be measured using tools that provide quantitative results 
related to the assessment of sleep, restoration of sleep architecture and improved symptom 
control, quality of life and mastery. The main outcome parameter for clinical trials in OSA is 
typically the AHI that is used to define severity of the disease. However, the following 
parameters can be used to further address objective assessments: 
• Nocturnal polysomnography results are the Gold standard to assess OSA severity and 
treatment efficacy (74). Certain indices derived from the polysomnography are of 
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importance when describing upper airway patency and functional assessment during 
sleep: 
A) Apnoea-hypopnoea index (AHI)  
The AHI is the number of apnoea’s (airflow absence for ≥ 10 seconds) and 
hypopnoeas (reduction in respiratory effort by ≥ 30%, associated with oxygen 
desaturation of ≥ 3% and/or arousal) per hour of recorded sleep. Excessive 
daytime sleepiness and an AHI greater than 5 are key features of OSA. The AHI is 
a standardised method that evaluates both severity and treatment outcome for 
OSA (mild OSA: AHI 5-14/hour, moderate OSA: AHI 15-30/hour, and severe 
OSA: AHI >30/hour) (75). The AHI does not assess the time spent in respiratory 
events or allow the differentiation of hypopnoeas or apnoeas (76). An incomplete 
reopening of the upper airway using an insufficient treatment may convert 
apnoeas into hypopnoeas, which would not be reflected accurately in the AHI. 
However, the AHI is a widely accepted tool for assessing OSA (52).  
- B) Oxygen Desaturation Index (ODI)   
The ODI can be recorded according to the desaturation threshold, most commonly 
the 3% or the 4% ODI are reported. The ODI is used to assess OSA in clinical 
settings and when tracking treatment of OSA (77-81).  
- C) Sleep Architecture  
This term refers to the cyclical pattern of sleep cycles and the preserved features 
of a hypnogram, including non-rapid eye movement (N1-3) and rapid eye 
movement (REM) sleep.  OSA causes disruption of the natural sleep architecture, 
with frequent arousals leading to numerous sleep stage shifts and abnormal 
cycling of sleep (82).  On CPAP therapy, patients with OSA have an improved 
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sleep quality (83). Similarly, the recording of the hypnogram can supplement the 
assessment of treatment and “task accomplishment”. 
- D) Arousal Index (AI) 
The AI is defined as the number of awakenings per hour during a recorded sleep 
study period, it is used in parallel to the hypnogram to understand sleep 
fragmentation and architecture (84). 
E) Snoring 
Snoring is a symptom associated with OSA that predominantly affects partners 
and others. However, the percentage of the night that patients snore may not 
reflect the severity of OSA (85), although there is a positive correlation between 
louder snoring and severe OSA (86).  
In addition, subjective assessments of “task accomplishment” are important, as patients need 
to be offered the opportunity to report on usage, sensation, expectation and efficacy of the 
treatment. The following tools may provide guidance for these assessments: 
• Epworth Sleepiness Scale (ESS)  
This is a commonly used questionnaire including eight questions about patient’s 
perception of sleepiness, scoring form “0” (not at all) to “3” (highly likely to doze). 
The minimal total score is “0” and the maximum “24” points (87). A score higher 
than 8 points has a 76% specificity for OSA (88) and treatments for OSA are 
considered effective if the ESS score improves. Accuracy can be improved through 
the use of a patient-partner consensus score (89, 90); pictorial (91) and online ESS 
(92) are used for screening. However, the ESS remains a subjective report and is 
subject to relevant sources of bias and inaccuracy (93). Despite its limitations, the 
minimal clinically important difference (MCID) for the ESS has been described as an 
improvement of more than two points (94). 
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• Berlin Questionnaire (BQ) 
This questionnaire is typically used to screen for OSA. The BQ includes questions 
about snoring, daytime somnolence, body mass index (BMI), and hypertension (95). 
It is a brief and validated screening tool that identifies people in the community who 
are at risk of OSA (96). It has a high sensitivity but low specificity (97, 98). 
• Stanford Sleepiness Scale (SSS) 
The SSS is a self-reported questionnaire to assess how awake the patient feels 
throughout the day (99). It can be used to compare sleepiness in hourly intervals of 
the day, for example prior to new treatment and to assess success thereafter. The SSS 
can be a useful measure to observe individual progress and to compare results with 
other studies (99). 
• Hospital Anxiety and Depression Scale (HADS)  
The HADS is a tool used for assessing anxiety and depression (100, 101). It is widely 
used in clinical practice and research. It contains fourteen straightforward questions 
(102). The link between depression/anxiety and chronic conditions like OSA is well 
reported (103). Hence, this tool is important in the assessment of how OSA affects the 
mental health of an individual. In addition, mental health disorders often co-exist with 
OSA. These conditions can include depression, anxiety, schizophrenia, bipolar 
disorder, post-traumatic stress disorder (PTSD) and substance use disorders (104). 
Used as a screening tool, the HADS can be added prior to commencing on new 
treatments, and repeatedly measured to follow up on the treatment effect (67). 
• Functional Outcomes of Sleep Questionnaire (FOSQ) 
This is a validated questionnaire to assess the impact of sleepiness on a patient’s 
ability to perform activities of daily living (ADLs) (105). The questionnaire contains 
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30 questions, covering 5 subscales (General Productivity, Social Outcome, Activity 
Level, Vigilance, Intimate Relationships and Sexual Activity) (106). 
• European Quality of Life five dimensions scale (EQ-5D)  
The EQ-5D is used for the standardised measurement of health outcomes (107, 108) 
and is available in 130 languages (109); the results can be used for reference-case 
analyses and for health-economics (110).  
• Other Questionnaires 
According to a systematic review of outcome measures for OSA, the most suitable 
additional assessments include the Maugeri OSA syndrome (MOSAS) questionnaire 
(quality of life), the sleep apnoea quality of life index (SAQLI), the OSA patient-
orientated severity index (OSAPOSI) and the Quebec sleep questionnaire (QSQ) 
(100, 111). 
The discussion about suitable outcome parameters in OSA remains contentious, partially due 
to the conflict of subjective vs objective disease burden (subjective symptoms vs objective 
disease severity). However, for any clinical trial it is important to capture enough data to 
describe the ‘syndrome’ (symptoms and sleep apnoea pathophysiology) and, thus, the 
TESLA home trial includes all of the above objective markers, including full 
polysomnography, and many of the symptom questionnaires plus some semi-quantitative 
interviews during the follow up period (see online supplement). 
 
Conclusion 
In order to assess a novel treatment method, as used in the TESLA home trial, it is important 
to understand additional components other than the primary outcome parameters of change in 
disease severity in response to treatment; these features define treatment uptake by addressing 
 14 
“usability”, “functionality” and “task accomplishment”. The conceptual framework for future 
studies using TESLA methodology acknowledges these key elements to address relevant 
guidelines, including those required by the NICE and the MHRA.  
The TESLA home programme incorporates the following points: 
• Development of a human factors engineering (HFE) programme within the 
existing product development process that satisfies regulations and standards. 
• Design of user interfaces that not only enable safe and effective user 
interactions, but are also perceived as usable and appealing by early and 
continuous involvement of the user (PPI). 
• Suitable labels and information for users that enable and enhance the user’s 
ability to engage with the product effectively and safely (112) and disseminate 
information from clinical trials and device performance. 
The proposed patient related outcome measures (PROMS) have been designed for future 
studies and could be used to test the efficacy of the treatment; accurate recording of PROMS 
will provide invaluable information from clinical trials to refine the method, optimise future 
treatment performance and design study protocols.  
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Legends: 
 
Figure 1: Schematic proposal of a conceptual framework TESLA. A: refers to “usability” to 
reflect the interaction between patient and device; B: refers to “functionality” to describe the 
link between device and task; C: refers to “task accomplishment” to assess the link between 
patient and task. 
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Figure 2: Picture of one of the prototypes of the TESLA programme attached to the 
submental area.  
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Figure 3: Ultrasound images of the genioglossus muscle, A: shows the relaxed muscle 
(without stimulation) in a coronal view, B: shows the muscle during electrical stimulation and 
the resulting change in the diameter caused by contraction. As the muscle contracts, it 
shortens, pulling the pharyngeal wall towards the anterior direction. An increase in the radius 
by +10% results in an approximate increase in the cross-sectional area (CSA) of the muscle 
of +21%, assuming a round model (CSA= π × r2). 
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Figure 4: Endoscopic images of the upper airway. The left panels show the upper airway 
with the vocal cords and the epiglottis while electrical stimulation is turned “off”, the right 
panel shows the same area when stimulation is turned “on”. The anterior-posterior diameter 
increases with stimulation, the tonsilla lingualis becomes visible just underneath the epiglottis 
when electrical stimulation is turned on (right lower panel). 
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